期刊文献+

Ad—TIMP-3转染增加宫颈癌细胞对顺铂的敏感性 被引量:2

Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer ceils to cisplatin
原文传递
导出
摘要 目的研究携带TIMP-3基因的重组腺病毒(Ad-TIMP-3)转染宫颈癌细胞后对顺铂(cDDP)敏感性的影响,探讨Ad-TIMP-3基因与cDDP联合在宫颈癌治疗中的作用。方法Ad-TIMP-3体外感染宫颈癌细胞系后,观察细胞凋亡效应、细胞周期及细胞内p53蛋白表达情况。Ad-TIMP-3与cDDP联合应用后,检测细胞克隆形成率;MTT法检测杀伤率及评价协同效应;裸鼠致瘤实验观察瘤体生长曲线。结果Ad-TIMP-3转染可促进细胞凋亡,引起细胞G2/M期阻滞,并诱导宫颈癌细胞内p53蛋白表达。Ad-TIMP-3与cDDP联合应用后,细胞克隆形成率明显减少,杀伤率成倍提高,肿瘤生长显著抑制。结论Ad-TIMP-3可增加宫颈癌对cDDP化疗的敏感性,二者联合应用在宫颈癌治疗中有潜在的应用价值。 Objective To investigate the effects of adenovirus-delivered tissue inhibitor of metalloproteinases-3 (Ad-TIMP-3) on sensitivity of cervical cancer cells to cisplatin and evaluate the potential application of this combined scheme in cervical cancer treatment. Methods Cells of cervical cancer CaSKi cell line were infected with Ad-TIMP-3 in vitro. Apoptotic effect, cell cycle changes and p53 protein expression were detected. After combined treatment of those cells with cisplatin, colony formation test was performed and cytotoxicity was detected by MTT. The growth curve and tumor growth inhibition in vivo were evaluated. Results The expressions of TIMP-3 mRNA and protein were significantly upregulated after transfection. As a result, massive apoptosis was induced and the cells were arrested at G2/M phase. Exogenous overexpression of TIMP-3 increased p53 protein level markedly in spite of the backgrounds of p53 gene in cells. Combined with cisplatin treatment, the cloning efficiency was decreased. A synergism was observed by isobolic method ( D 〈 1 ) in vitro and tumor growth was significantly inhibited in vivo. Conclusion Ad-TIMP-3 is a powerful proapoptotic agent. It increases sensitivity of the cells to cisplatin and the Ad-TIMP-3 gene therapy in combination with cisplatin could be a promising alternative in cervical cancer treatment.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2007年第1期25-29,共5页 Chinese Journal of Oncology
基金 首都医学发展基金资助项目(2002-2008)
关键词 TIMP-3基因 腺病毒 基因治疗 顺铂 宫颈肿瘤 TIMP-3 Adenovirus Gene therapy Cisplatin Cervical neoplasms
  • 相关文献

参考文献13

  • 1Inoue A, Narumi K, Matsubara N, et al. Administration of wild-typep 53 adenoviral vector synergistically enhances the cytotoxicity of anticancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett, 2000, 157:105-112.
  • 2Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis, 2006, 27 : 1160-1168.
  • 3Brueckl WM, Grombach J, Wein A, et al. Alterations in the tissue inhibitor of metalloproteinase-3 ( TIMP-3 ) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). Cancer Lett, 2005, 223 : 137-142.
  • 4Youm MY, Kim YN, Lee KB, et al. Promoter methylation of p16,DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer, 2006,16 : 1234-1240.
  • 5Tran PL, Vigneron JP, Pericat D, et al. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther, 2003, 10:435-444.
  • 6孙建新,张从昕,殷学平,吴祥甫.重组金属蛋白酶抑制因子-3抗肿瘤作用的实验研究[J].中华肿瘤杂志,1998,20(4):287-289. 被引量:16
  • 7Sheu BC, Lien HC, Ho HN, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res, 2003, 63:6537-6542.
  • 8Bond M, MurpHy G, Bennett MR, et al. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type Ⅱ apoptotic pathway. J Biol Chem, 2002, 275 : 13787-13795.
  • 9Sax JK, El-Deity WS. p53 downstream targets and chemosensitivity.Cell Death Differ, 2003, 10:413-417.
  • 10Cheah PL, Looi LM. p53 immunohistoehemical expression :messages in cervical carcinogenesis. Pathology, 2002, 34:326-331.

二级参考文献13

  • 1Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res, 2000,60:3655-3661.
  • 2Zhang EP, Lian PG, Cai KL,et al. Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys, 1989,16:301-305.
  • 3Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys, 1992,23:261-270.
  • 4Kanegae Y, Makimura M,Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol, 1994,47:157-166.
  • 5Brand K, Klocke R, Possling A, et al. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther, 1999, 6: 1054-1063.
  • 6Li JH, Lax SA, Kim J, et al. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 1999, 43:607-616.
  • 7Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 1998,16:2221-2232.
  • 8Clayman GL, Frank DK, Bruso PA, et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res, 1999, 5:1715-1722.
  • 9Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999, 91:763-771.
  • 10Habib NA, Hodgson HJ, Lemoine N, et al. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther, 1999,10:2019-2034.

共引文献38

同被引文献30

  • 1程晓东,吕卫国,叶枫,陈怀增,谢幸.局部晚期子宫颈癌新辅助化疗价值的评估[J].中华妇产科杂志,2006,41(2):95-98. 被引量:66
  • 2王蔚文.临床疾病诊断与疗效判断标准[S].北京:科学技术文献出版社,2010:592.
  • 3李希聪(综述),何涛(综述),李振伟(审校).宫颈癌的新辅助化疗[J].国际肿瘤学杂志,2007,34(8):621-623. 被引量:3
  • 4Vrdoljak E,Hamm W. Current state-of-the-art of con- eomitant chemoradiation in cervical carcinomas [J]. Eur Gynaeeol Oneol,2003,3(6) :475-479.
  • 5Benedet JL,Bender H,Jcm H,et al. FIGO staging vlas- sifications and clinical practice guidelines in Ihc manage- menl of gynecologic cancer. FIGO Committee on Gytwco- logic Ontology [J]. lnt J Gynaecol Obste,2000,70 (2) : 209-262.
  • 6Frei E. Clinical cancer research:ml elutlaliled species [J]. J Cancer, 1982,50(10) : 1979-1992.
  • 7Eeke TH,Schlechte HH,Sehiemenz K,et al. TP53 gent, mutations in prostate cancer progression [J]. Anticanccr Res, 2010,30(5) : 1579-1586.
  • 8Swisher SG,Roth JA, Komaki R,et al. Induction of p53- regulated genes and tumor regression in hmg cancer pa- tients after intratumoral delivery of adenoviral p53 (IN- GN 201) and radiation therapy [J]. Clin Cancer Res, 2003,9( 1):93-101.
  • 9LIU YL,Zheng XL,Liu FM. The mechanism and in- hibitory effect of recombinant human P53 adenovirus in- jection combined with paclilaxel on human cervical can- cer cell HeLa[ J]. Eur European Review for Melical an Pharmacological Sciences,2015, 19(6):1037-1042.
  • 10Fontanini G,Boldrini L,Vignati S,et al. Bei-2 anti P53 regulate Vascular endothelial grolh factor(VEGF) medi- ated angiogen-esis in non-small-cell lung carcinoma [J]. Eur J Cancer, 1998,34(5) :718-723.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部